Xi Liu
Fondateur chez BEIJING STRONG BIOTECHNOLOGIES,INC.
Fortune : 171 M $ au 30/04/2024
Postes actifs de Xi Liu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Directeur/Membre du Conseil | 29/03/2001 | - |
| Directeur Général | 16/03/2011 | - | |
| Fondateur | 29/03/2001 | - | |
Fuzhou Maixin Biotech Co., Ltd.
 Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Directeur/Membre du Conseil | 30/09/2020 | - |
Historique de carrière de Xi Liu
Formation de Xi Liu
| Harbin Engineering University | Graduate Degree |
| Institute of Automation Chinese Academy of Sciences | Doctorate Degree |
Statistiques
Internationale
| Chine | 5 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
